fyi
Special Issue "Bacterial Vaginosis - Existing Challenges to Successful Therapy"
A special issue of Pathogens (ISSN 2076-0817).
Deadline for manuscript submissions: 30 September 2022.
Share This Special Issue
mce-anchorSpecial Issue Editors
Prof. Dr. Jack Sobel E-Mail Website
Guest Editor
Internal Medicine Unit, Wayne State University School of Medicine, Detroit, MI, USA
Interests: internal medicine; immunology and microbiology; obstetrics and gynecology
Prof. Dr. Christina Muzny E-Mail Website
Guest Editor
Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA
Interests: pathogenesis; epidemiology; diagnosis, treatment, and prevention of bacterial vaginosis and trichomoniasis
mce-anchorSpecial Issue Information
Dear Colleagues,
Bacterial vaginosis (BV), the most common cause of vaginal infection worldwide, continues to provide multiple major challenges to successful treatments and cures. Progress is handicapped by multiple areas of poor and inadequate understanding of the pathogenesis of BV. The clinical syndrome clearly encases a variable microbiota both qualitatively and quantitatively, hence the frequently unpredictable clinical course, prognosis, and response to antimicrobial therapy. So many questions remain unanswered. Although diagnostic modalities have progressed from useful but highly subjective criteria (Amsel) to less subjective microscopy (Nugent) and quantitative molecular methods including PCR and next generation sequencing that allow commercial access, the data generated still beg more questions than ever and enhance the complexity of this syndrome. Each year we add to the list of consequences and complications of BV in gravid and non-gravid females alike. However, it is in the realm of therapy that we sadly lag, fueled by a continued lack of a clear understanding of pathophysiology and, not surprisingly, by a continued empty therapeutic pipeline. Frustration continues to dominate modern referral clinics, which is evident in patients and practitioners alike. The proposed Special Issue will highlight and target these many deficiencies while focussing on the unacceptably high recurrence rate of symptomatic disease and, in the absence of available antimicrobials, review treatment strategies.
Prof. Dr. Jack Sobel
Prof. Dr. Christina Muzny
https://www.infectiousdiseaseadviso...cine/infectious-diseases/bacterial-vaginosis/
- Forums
- ASX - By Stock
- SPL
- Key Opinion Leader Jack Sobel
Key Opinion Leader Jack Sobel
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.8¢ |
Change
0.001(1.03%) |
Mkt cap ! $40.97M |
Open | High | Low | Value | Volume |
9.7¢ | 9.9¢ | 9.7¢ | $44.76K | 455.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 824859 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.0¢ | 121525 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 824859 | 0.095 |
1 | 61400 | 0.092 |
2 | 300000 | 0.091 |
2 | 311111 | 0.090 |
1 | 400000 | 0.089 |
Price($) | Vol. | No. |
---|---|---|
0.100 | 121525 | 5 |
0.105 | 179684 | 6 |
0.110 | 202467 | 5 |
0.115 | 103392 | 3 |
0.120 | 150305 | 10 |
Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |